跳至主要内容
临床试验/NL-OMON50664
NL-OMON50664招募中不适用

An exploratory analysis of markers in blood, faeces and the colonic mucosa regarding response to treatment with infliximab for acute severe ulcerative colitis - Mechanisms for Infliximab (non)response in acute severe ulcerative colitis

Academisch Medisch Centrum0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. At least 16 years of age.
  • 2. A documented diagnosis of UC prior to entry into the study, based on
  • clinical, biochemical, endoscopic and histological findings(14).
  • 3. ASUC as defined by the Truelove and Witts criteria as six or more stools a
  • day with either large amounts of blood per stool, a temperature over 37.8 °C, a
  • heart rate above 90 bpm, hemoglobin levels of less than 10.5 g/dL, or an
  • erythrocyte sedimentation rate over 30 mm/h(1).
  • 4. Patients not responding to intravenous corticosteroid treatment and
  • receiving IFX as rescue therapy
  • 5. Patients who are not yet candidates for emergency colectomy.
  • 6. Signed and dated informed consent.

排除标准

  • 1.Other cause of colitis: indeterminate colitis, microscopic colitis, ischemic
  • colitis, infectious colitis, or clinical findings suggestive of Crohn*s
  • 2.Positive stool examinations for enteric pathogens, pathogenic ova or
  • parasites, or Clostridium difficile toxin.
  • 3.Contra-indications to anti-TNFa treatment (TBC, severe infections or
  • congestive heart failure)
  • 4.IFX or any other anti-TNFa therapy in the past six months.
  • 5. Pregnant or lactating females.

研究者

相似试验

An exploratory analysis of markers in blood, faeces... | 临床试验